Detalhe da pesquisa
1.
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.
Clin Cancer Res
; 27(10): 2723-2733, 2021 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33622704
2.
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
Leukemia
; 34(11): 2903-2913, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32733012
3.
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy.
Cancers (Basel)
; 11(12)2019 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31835495
4.
Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers.
J Cancer Res Clin Oncol
; 132(4): 265-74, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16374613
5.
Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
Clin Cancer Res
; 9(12): 4376-86, 2003 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14555509
6.
Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?
J Cancer Res Clin Oncol
; 129(7): 397-409, 2003 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12836015
7.
Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1.
J Invest Dermatol
; 127(4): 835-45, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17235328
8.
A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.
Cancer Immunol Immunother
; 54(2): 129-40, 2005 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15365776